Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Ketamine has demonstrated rapid antidepressant effects in patients with treatment-resistant depression (TRD); however, the safety and tolerability of ketamine in this population have not been fully described. Herein we report the largest study to date of the safety, tolerability, and acceptability of ketamine in TRD.
Data from 205 IV ketamine infusions (0.5 mg/kg over 40 minutes) in 97 participants with DSM-IV–defined major depressive disorder were pooled from three clinical trials conducted between 2006 and 2012 at two academic medical centers. Safety and tolerability measures included attrition, adverse events, hemodynamic changes, and assessments of psychosis and dissociation.
READ FULL ARTICLE
From www.psychiatrist.com
